Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $38 Price Target
Abeona Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Abeona Therapeutics (ABEO)
SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $6
Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $40 From $22, Maintains Overweight Rating
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $40
Abeona Therapeutics (ABEO) Gets a Hold From SVB Securities
Alliance Global Starts Abeona Therapeutics at Buy With $20 Price Target
SVB Securities Keeps Their Hold Rating on Abeona Therapeutics (ABEO)
Abeona Therapeutics Is Maintained at Market Perform by SVB Leerink
Abeona Therapeutics Price Target Raised to $5.00/Share From $1.00 by SVB Leerink
SVB Leerink Maintains Market Perform on Abeona Therapeutics, Raises Price Target to $5
No Data